Hoshi K, Mizushima Y, Shiokawa Y, Kageyama T, Honma M, Kashiwazaki S, Shichikawa K, Tsunematsu T, Kaneko K
Department of Internal Medicine, St. Marianna University, Kawasaki, Japan.
Drugs Exp Clin Res. 1985;11(9):621-6.
A multicentre double-blind comparative trial was performed in 138 patients with rheumatoid arthritis (RA) after biweekly intravenous or intramuscular injections of liposteroid (containing 2.5 mg of dexamethasone), which had been developed as a drug for targeting therapy of RA, and Decadron (containing 3.3 mg of dexamethasone) as a reference drug. The results showed a tendency to a significantly higher rate of improvement with lower frequency of side-effects in the liposteroid group than in the Decadron group. This study indicates that liposteroid is more useful for RA and that the separation of the efficacy and side-effects of steroids could be clinically confirmed to some extent.
对138例类风湿关节炎（RA）患者进行了一项多中心双盲对照试验。患者每两周接受一次静脉或肌肉注射脂质体类固醇（含2.5毫克地塞米松），该脂质体类固醇是作为一种用于RA靶向治疗的药物研发的，同时将地塞米松磷酸钠（含3.3毫克地塞米松）作为对照药物。结果显示，脂质体类固醇组的改善率明显更高，且副作用发生率更低。这项研究表明，脂质体类固醇对RA更有效，并且在一定程度上可以在临床上证实类固醇的疗效和副作用是可以分离的。
